Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EGRX Eagle Pharmaceuticals Inc

0.62 (10.58%)
After Hours
Last Updated: 20:00:00
Delayed by 15 minutes


Draw Mode:

Volume 188,309
Bid Price 6.16
Ask Price 7.03
News (3)
Day High 6.81


52 Week Range


Day Low 5.86
Company Name Stock Ticker Symbol Market Type
Eagle Pharmaceuticals Inc EGRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.62 10.58% 6.48 20:00:00
Open Price Low Price High Price Close Price Prev Close
5.89 5.86 6.81 6.48 5.86
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,087 188,309 $ 6.52 $ 1,227,321 - 4.10 - 32.44
Last Trade Time Type Quantity Stock Price Currency
18:16:47 13 $ 6.80 USD

Eagle Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
84.03M 12.99M - 316.61M 35.64M 2.74 2.36
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Eagle Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No EGRX Message Board. Create One! See More Posts on EGRX Message Board See More Message Board Posts

Historical EGRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.856.815.736.24133,7730.6310.77%
1 Month5.996.814.595.57237,3900.498.18%
3 Months6.056.814.105.15279,2980.437.11%
6 Months17.1618.164.107.25207,647-10.68-62.24%
1 Year28.0432.444.1014.30195,909-21.56-76.89%
3 Years44.8558.254.1029.84151,595-38.37-85.55%
5 Years50.2964.944.1038.13152,931-43.81-87.11%

Eagle Pharmaceuticals Description

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Your Recent History

Delayed Upgrade Clock